Vimta Labs (524394) investor relations material

Executive summary

• Q3 FY26 total income was ₹1,005 million, up 10.2% year-over-year, driven by pharmaceutical and food testing services.

• Nine months FY26 total income reached ₹3,043 million, up 20.7% year-over-year.

• EBITDA margins remained robust at 34.3% for Q3 and 35.1% for 9M, with PAT margins at 17.5% and 18.5% respectively.

• EPS stood at ₹3.96 for Q3 and ₹12.67 for 9M FY26.

• Unaudited financial results for the quarter and nine months ended December 31, 2025, were reviewed and approved by the Audit Committee and Board on January 28, 2026.

Financial highlights

• Q3 FY26 EBITDA was ₹344 million, PBT ₹234 million, and PAT ₹176 million, all including exceptional items.

• Nine months FY26 EBITDA reached ₹1,068 million, PBT ₹749 million, and PAT ₹564 million.

• Cash and cash equivalents at the end of 9M FY26 were ₹666.6 million.

• Q3 FY26 saw a CAPEX cash outflow of ₹248.3 million.

• Bonus shares issued in June 2025 in a 1:1 ratio, with prior period EPS restated accordingly.

Outlook and guidance

• Management remains confident in near- and long-term growth, citing favorable market conditions and capacity expansions.

• Q4 is expected to be stronger, following historical trends and seasonal benefits in food testing.

• The INR 500 crore annual revenue target may not be fully achieved this year, but management expects a satisfactory outcome.

• Biologics contract research and development services to be commercialized in Q1 next fiscal, with initial focus on client acquisition.

• The company will continue to monitor the impact of the new labour code and provide updates as needed.